347 related articles for article (PubMed ID: 32705942)
1. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.
Fiorucci D; Milletti E; Orofino F; Brizzi A; Mugnaini C; Corelli F
J Biomol Struct Dyn; 2021 Oct; 39(16):6242-6248. PubMed ID: 32705942
[TBL] [Abstract][Full Text] [Related]
2. In-silico drug repurposing for targeting SARS-CoV-2 main protease (M
Sharma S; Deep S
J Biomol Struct Dyn; 2022 Apr; 40(7):3003-3010. PubMed ID: 33179568
[TBL] [Abstract][Full Text] [Related]
3. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
[TBL] [Abstract][Full Text] [Related]
4.
El-Hddad S; Sobhy M; Ayoub A; El-Adl K
J Biomol Struct Dyn; 2023 Nov; 41(19):9267-9281. PubMed ID: 36399002
[TBL] [Abstract][Full Text] [Related]
5. Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2.
Shode FO; Idowu ASK; Uhomoibhi OJ; Sabiu S
J Biomol Struct Dyn; 2022 Sep; 40(14):6587-6602. PubMed ID: 33590806
[TBL] [Abstract][Full Text] [Related]
6. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
7. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
[TBL] [Abstract][Full Text] [Related]
8.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
9. Identification of natural inhibitors against Mpro of SARS-CoV-2 by molecular docking, molecular dynamics simulation, and MM/PBSA methods.
Sharma P; Joshi T; Mathpal S; Joshi T; Pundir H; Chandra S; Tamta S
J Biomol Struct Dyn; 2022 Apr; 40(6):2757-2768. PubMed ID: 33143552
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
[TBL] [Abstract][Full Text] [Related]
11. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
12. Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets.
Almeida JSFD; Botelho FD; de Souza FR; Dos Santos MC; Goncalves ADS; Rodrigues RLB; Cardozo M; Kitagawa DAS; Vieira LA; Silva RSF; Cavalcante SFA; Bastos LDC; Nogueira MOT; de Santana PIR; Brum JOC; Nepovimova E; Kuca K; LaPlante SR; Galante EBF; Franca TCC
J Biomol Struct Dyn; 2022 Jul; 40(11):5229-5242. PubMed ID: 33416020
[TBL] [Abstract][Full Text] [Related]
13. Repositioning of anti-dengue compounds against SARS-CoV-2 as viral polyprotein processing inhibitor.
Bajrai LH; Faizo AA; Alkhaldy AA; Dwivedi VD; Azhar EI
PLoS One; 2022; 17(11):e0277328. PubMed ID: 36383621
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2.
Sharma P; Vijayan V; Pant P; Sharma M; Vikram N; Kaur P; Singh TP; Sharma S
J Biomol Struct Dyn; 2021 Oct; 39(17):6649-6659. PubMed ID: 32741313
[TBL] [Abstract][Full Text] [Related]
15. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C
J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168
[TBL] [Abstract][Full Text] [Related]
16. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
17. Finding potent inhibitors for COVID-19 main protease (M
Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
[TBL] [Abstract][Full Text] [Related]
18. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
Farhat N; Khan AU
J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
[TBL] [Abstract][Full Text] [Related]
19. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an
Mahanta S; Chowdhury P; Gogoi N; Goswami N; Borah D; Kumar R; Chetia D; Borah P; Buragohain AK; Gogoi B
J Biomol Struct Dyn; 2021 Jul; 39(10):3802-3811. PubMed ID: 32406317
[TBL] [Abstract][Full Text] [Related]
20. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
Kundu D; Selvaraj C; Singh SK; Dubey VK
J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
